Get it on Google Play

Eisai completes FDA submission for LEQEMBI subcutaneous starting dose

November 26, 2025 6:03 AM UTC Send to a Friend
Eisai Co., Ltd. and Biogen Inc. (NASDAQ: BIIB) announced that Eisai has completed its rolling submission of a Supplemental Biologics ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login